Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01107522 | Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas | unknown | Phase 1 | 100 | Tactical Therapeutics, Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06462716 | A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | Chengdu Baiyu Pharmaceutical Co., Ltd.INDUSTRY |
| 1 |
| Apr 13, 2025 |
| clinicaltrials |
| NCT06527300 | A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer | unknown | Phase 2 | 48 | Zhejiang Wenda Pharma Technology LTD.INDUSTRY | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06541301 | PICC-ports Versus Chest - Ports for Long Term Chemotherapy Deliverance in Oncology Patients(PICCHEST) | unknown | N/A | 852 | European Institute of OncologyOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05650242 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors | unknown | Phase 1 | 177 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06410703 | CAN1012 Combined With PD-1 in Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 71 | Canwell Biotech LimitedINDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06322095 | A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors | unknown | Phase 2 | 72 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06413615 | A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors | unknown | Phase 2 | 150 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT04740398 | A Study of CBP-1008 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 143 | Coherent Biopharma (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04928612 | A Study of CBP-1018 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 170 | Coherent Biopharma (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 28, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04185831 | A MolEcularly Guided Anti-Cancer Drug Off-Label Trial(MEGALiT) | unknown | Phase 2 | 167 | Uppsala University HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06404281 | γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors | unknown | Phase 1 | 9 | Changzhou No.2 People's HospitalOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04304066 | Research for the Molecular Imaging of the PD-L1 Targeting Tracer | unknown | N/A | 50 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06553846 | A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | Fudan UniversityOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT03658785 | Immunotherapy for the Treatment of Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Tongji HospitalOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT05244551 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 85 | Abbisko Therapeutics Co, LtdINDUSTRY | 2 | Aug 12, 2024 | clinicaltrials |
| NCT05266612 | Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 | 12 | Virogin Biotech Canada LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT04282031 | A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer | unknown | Phase 1 / Phase 2 | 224 | Beta Pharma (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05076552 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer | unknown | Phase 1 | 30 | Tachyon Therapeutics, Inc.INDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06199908 | AMT-562 in Patients With Selected Advanced Solid Tumors | unknown | Phase 1 | 72 | Multitude Therapeutics (Australia) Pty LtdINDUSTRY | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06519110 | Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations(CVL009-C2001) | unknown | Phase 2 | 60 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 0 | Jul 25, 2024 | clinicaltrials |
| NCT05707325 | Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies(Reboot-101) | unknown | Early Phase 1 | 30 | Westlake TherapeuticsINDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05731752 | Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 80 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06512896 | Clinical Study on Intraluminal Injection of FOLactis | unknown | N/A | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT05183243 | GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results | unknown | Phase 1 | 68 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05620862 | Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors | unknown | Phase 1 | 68 | Sun Yat-sen UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05880043 | GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 50 | GI Cell, Inc.INDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06329206 | A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 156 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06490068 | Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy | unknown | Phase 2 | 10 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06439589 | Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 88 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03694249 | Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence | unknown | Phase 2 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT05830045 | A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 180 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06473948 | To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects | unknown | Phase 1 | 27 | JemincareINDUSTRY | 0 | Jun 25, 2024 | clinicaltrials |
| NCT05819684 | A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 | 133 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06469268 | Development and Application Study of ePRO Software for Managing Cancer Patients Throughout the Treatment Period | unknown | N/A | 100 | Shikai WuOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06466265 | Study of DNP002 in Patients With Solid Tumors | unknown | Phase 1 | 36 | Kumho HT Inc.INDUSTRY | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06233292 | A Study of ZG005 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 484 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06239298 | A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 130 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06094777 | A Study of HY-0102 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06443307 | Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan | unknown | — | 933 | Peking UniversityOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06136065 | 68 Gallium-Fibroblast Activating Protein Inhibitors-46 Positron Emission Tomography - Computerized Tomography for Molecular Assessment of Fibroblast Activation and Risk Assessment in Solid Tumors(FAPI) | unknown | Phase 2 | 100 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06433726 | A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Chengdu Baiyu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT05605197 | U87 CART in Treatment of Advanced Solid Tumor | unknown | Phase 1 | 12 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | May 28, 2024 | clinicaltrials |
| NCT06431529 | A Study of Tumor Neoantigen-specific T Cells in the Treatment of Advanced Solid Tumors(Neoantigen-T) | unknown | Early Phase 1 | 6 | JIANG LONGWEIOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT04092673 | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies(Zotatifin) | unknown | Phase 1 / Phase 2 | 30 | Effector TherapeuticsINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05564858 | A Study of FDA022-BB05 in Subjects With Advanced Solid Malignant Tumors | unknown | Phase 1 | 107 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT05650580 | TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors | unknown | Phase 1 | 26 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT05751356 | TR128 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | Tarapeutics Science Inc.INDUSTRY | 1 | May 14, 2024 | clinicaltrials |
| NCT03004755 | The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study(PEACE) | unknown | — | 500 | University College, LondonOTHER | 1 | May 10, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Sep 9, 2025source: clinicaltrials